Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn

NCT01006798 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.

NCT NCT01006798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01006798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn
Lead sponsor
Emergent BioSolutions
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2009
Completion date
September 30, 2011
Enrollment
166 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bird flu, influenza